

# Pietro Invernizzi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8742349/pietro-invernizzi-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

353  
papers

18,462  
citations

68  
h-index

125  
g-index

419  
ext. papers

23,035  
ext. citations

7.4  
avg, IF

6.81  
L-index

#	Paper	IF	Citations
353	EASL Clinical Practice Guidelines: management of cholestatic liver diseases. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 237-67	13.4	1234
352	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1522-1534	59.2	913
351	Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 261-80	24.2	618
350	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 631-43	59.2	574
349	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 145-172	13.4	512
348	Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. <i>Gastroenterology</i> , <b>2004</b> , 127, 485-92	13.3	378
347	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 557-588	24.2	355
346	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , <b>2010</b> , 42, 658-60	36.3	337
345	Macrophage plasticity and polarization in liver homeostasis and pathology. <i>Hepatology</i> , <b>2014</b> , 59, 2034-42	11.2	274
344	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , <b>2013</b> , 45, 670-5	36.3	267
343	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , <b>2014</b> , 147, 1338-49.e5; quiz e15	13.3	265
342	Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. <i>Hepatology</i> , <b>1997</b> , 25, 1090-5	11.2	244
341	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , <b>2015</b> , 149, 1804-1812.e4	13.3	235
340	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. <i>Hepatology</i> , <b>2003</b> , 38, 1250-7	11.2	228
339	Frequency of monosomy X in women with primary biliary cirrhosis. <i>Lancet, The</i> , <b>2004</b> , 363, 533-5	40	221
338	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
337	The X chromosome and immune associated genes. <i>Journal of Autoimmunity</i> , <b>2012</b> , 38, J187-92	15.5	199

336	New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. <i>Journal of Autoimmunity</i> , <b>2008</b> , 30, 84-9	15.5	194
335	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , <b>2015</b> , 6, 8019	17.4	185
334	Definition of human autoimmunity--autoantibodies versus autoimmune disease. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, A259-66	13.6	171
333	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1216-1228	13.4	163
332	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1063-1071	13.4	158
331	Apoptoses and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , <b>2009</b> , 49, 871-9	11.2	158
330	X chromosome monosomy: a common mechanism for autoimmune diseases. <i>Journal of Immunology</i> , <b>2005</b> , 175, 575-8	5.3	157
329	Biliary apoptoses and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. <i>Hepatology</i> , <b>2010</b> , 52, 987-98	11.2	154
328	Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. <i>Journal of Autoimmunity</i> , <b>2016</b> , 66, 40-50	15.5	152
327	Autoimmune liver serology: current diagnostic and clinical challenges. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 3374-87	5.6	151
326	Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. <i>Hepatology</i> , <b>2006</b> , 43, 1135-44	11.2	148
325	Antinuclear antibodies in primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , <b>2005</b> , 25, 298-310	7.3	146
324	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 269-273	36.3	140
323	MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 305-14	13.6	133
322	Female predominance and X chromosome defects in autoimmune diseases. <i>Journal of Autoimmunity</i> , <b>2009</b> , 33, 12-6	15.5	132
321	Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. <i>Gut</i> , <b>2002</b> , 51, 265-9	19.2	130
320	Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 366-72	13.4	130
319	A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. <i>Hepatology</i> , <b>2007</b> , 45, 659-65	11.2	129

318	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 5209-21	5.6	122
317	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 505-515	13.4	113
316	Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. <i>Hepatology</i> , <b>2007</b> , 46, 456-62	11.2	108
315	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , <b>2016</b> , 65, 321-9	19.2	107
314	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 436-42	15.5	103
313	Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. <i>Gastroenterology</i> , <b>2004</b> , 127, 493-501	13.3	101
312	The consequences of apoptosis in autoimmunity. <i>Journal of Autoimmunity</i> , <b>2008</b> , 31, 257-62	15.5	98
311	Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , <b>2008</b> , 48, 1906-12	11.2	98
310	Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 905-12	13.4	96
309	Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. <i>Oncogene</i> , <b>2016</b> , 35, 671-82	9.2	95
308	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 173, 250-8	6.2	94
307	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. <i>Hepatology</i> , <b>2012</b> , 55, 153-60	11.2	93
306	Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. <i>Gut</i> , <b>2012</b> , 61, 268-77	19.2	93
305	Changing nomenclature for PBC: From Cirrhosis to Cholangitis. <i>Hepatology</i> , <b>2015</b> , 62, 1620-2	11.2	92
304	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 102-115	13.4	91
303	Interpreting serological tests in diagnosing autoimmune liver diseases. <i>Seminars in Liver Disease</i> , <b>2007</b> , 27, 161-72	7.3	87
302	Iron levels in polarized macrophages: regulation of immunity and autoimmunity. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 883-9	13.6	86
301	Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF- $\beta$ receptor type II mouse. <i>Journal of Autoimmunity</i> , <b>2013</b> , 41, 111-9	15.5	85

300	Genetics and geoeidemiology of primary biliary cirrhosis: following the footprints to disease etiology. <i>Seminars in Liver Disease</i> , <b>2005</b> , 25, 265-80	7.3	85
299	Autophagy: highlighting a novel player in the autoimmunity scenario. <i>Journal of Autoimmunity</i> , <b>2007</b> , 29, 61-8	15.5	83
298	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , <b>2016</b> , 6, 25906	4.9	82
297	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 357-365	13.4	80
296	A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 34, 55-8	15.5	80
295	Infectome: a platform to trace infectious triggers of autoimmunity. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 726-40	13.6	77
294	Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. <i>Cancer Research</i> , <b>2008</b> , 68, 9184-93	10.1	75
293	Y chromosome loss in male patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2013</b> , 41, 87-91	15.5	73
292	From bases to basis: linking genetics to causation in primary biliary cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 401-10	6.9	72
291	Etiopathogenesis of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 3328-37	5.6	72
290	Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 1202-9	13.4	71
289	Geoeidemiology of autoimmune liver diseases. <i>Journal of Autoimmunity</i> , <b>2010</b> , 34, J300-6	15.5	69
288	Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 401-6	13.4	69
287	Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 813-20	13.4	68
286	The genetics of human autoimmune disease. <i>Journal of Autoimmunity</i> , <b>2009</b> , 33, 290-9	15.5	68
285	Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice. <i>Gastroenterology</i> , <b>2014</b> , 146, 1795-808.e12	13.3	67
284	Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. <i>Hepatology</i> , <b>2011</b> , 54, 714-23	11.2	67
283	Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. <i>Hepatology</i> , <b>1999</b> , 29, 320-7	11.2	67

282	Clinical pharmacokinetics of therapeutic bile acids. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 30, 333-58	6.2	67
281	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , <b>2015</b> , 7, 61	7.7	66
280	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , <b>2012</b> , 13, 461-8	4.4	66
279	Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. <i>Hepatology</i> , <b>2014</b> , 60, 1314-23	11.2	64
278	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , <b>2011</b> , 6, 95-102	5.7	64
277	Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2005</b> , 24, 347-52	15.5	62
276	Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 300-4	13.6	61
275	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 626-634	18.8	60
274	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , <b>2016</b> , 185, 61-71	6.2	59
273	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 176-80	15.5	58
272	Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 100	3	58
271	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 198-207	13.4	57
270	Progress in the genetics of primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , <b>2011</b> , 31, 147-56	7.3	57
269	Changing nomenclature for PBC: from PcirrhosisPto PcholangitisP. <i>Gastroenterology</i> , <b>2015</b> , 149, 1627-9	13.3	56
268	Presence of fetal DNA in maternal plasma decades after pregnancy. <i>Human Genetics</i> , <b>2002</b> , 110, 587-91	6.3	56
267	The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor- $\beta$ biliary secretion in mice. <i>Hepatology</i> , <b>2016</b> , 64, 865-79	11.2	56
266	Changing nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1285-7	13.4	55
265	Autoimmunity and TurnerP syndrome. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, A538-43	13.6	55

264	Update on primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 401-8	3.3	54
263	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2013</b> , 46, 81-7	15.5	52
262	Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. <i>Hepatology</i> , <b>2017</b> , 66, 528-541	11.2	51
261	Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. <i>Hepatology</i> , <b>2016</b> , 64, 1202-1216	11.2	51
260	Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2012</b> , 42, 288-97	12.3	50
259	Blood fetal microchimerism in primary biliary cirrhosis. <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 122, 418-22	6.2	50
258	Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. <i>Clinical and Experimental Immunology</i> , <b>1998</b> , 114, 448-54	6.2	49
257	Epidemiology and pathogenesis of primary biliary cirrhosis. <i>Journal of Clinical Gastroenterology</i> , <b>2004</b> , 38, 264-71	3	49
256	Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 723-732	6.1	48
255	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , <b>2011</b> , 54, 196-203	11.2	48
254	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. <i>Journal of Autoimmunity</i> , <b>2012</b> , 38, J193-6	15.5	47
253	The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 215-222	13.6	47
252	Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 128	8.4	46
251	Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 2143-6	0.7	46
250	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , <b>2019</b> , 105, 102328	15.5	45
249	X monosomy in female systemic lupus erythematosus. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1110, 84-91	6.5	45
248	Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 451-9	8	45
247	Geographic clusters of primary biliary cirrhosis. <i>Clinical and Developmental Immunology</i> , <b>2003</b> , 10, 127-31		45

246	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , <b>2013</b> , 14, 179-86	4.4	44
245	Future directions in genetic for autoimmune diseases. <i>Journal of Autoimmunity</i> , <b>2009</b> , 33, 1-2	15.5	44
244	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 254-264	0.7	44
243	Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. <i>Cellular and Molecular Immunology</i> , <b>2010</b> , 7, 1-10	15.4	42
242	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. <i>American Journal of Physiology - Renal Physiology</i> , <b>2011</b> , 301, G623-33	5.1	41
241	Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 712-7	13.4	40
240	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 453-455	13.4	40
239	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , <b>2017</b> , 37, 1554-1561	7.9	39
238	Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 17667	7.9	39
237	Skewing of X chromosome inactivation in autoimmunity. <i>Autoimmunity</i> , <b>2008</b> , 41, 272-7	3	39
236	Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. <i>Hepatology</i> , <b>2009</b> , 50, 546-54	11.2	38
235	Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 809-15	4	38
234	Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. <i>Journal of Autoimmunity</i> , <b>2013</b> , 46, 1-6	15.5	37
233	Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. <i>Hepatology</i> , <b>2005</b> , 41, 55-63	11.2	37
232	Vitamin D in autoimmune liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, 535-45	2.4	36
231	Primary biliary cirrhosis: does X mark the spot?. <i>Autoimmunity Reviews</i> , <b>2004</b> , 3, 493-9	13.6	36
230	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102618	13.6	36
229	Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. <i>FASEB Journal</i> , <b>2017</b> , 31, 4305-4324	0.9	35

228	Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. <i>Laboratory Investigation</i> , <b>2016</b> , 96, 1256-1267	5.9	35
227	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , <b>2016</b> , 65, 1998-2006	19.2	35
226	Genetics and epigenetics of primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 255-64	7.3	35
225	Towards common denominators in primary biliary cirrhosis: the role of IL-12. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 731-3	13.4	35
224	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 60-5	3.3	35
223	Genes and (auto)immunity in primary biliary cirrhosis. <i>Genes and Immunity</i> , <b>2005</b> , 6, 543-56	4.4	35
222	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , <b>2018</b> , 67, 1920-1930	11.2	35
221	Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 162-6	13.6	34
220	Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 2112-22	7.5	34
219	Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. <i>Human Reproduction</i> , <b>2014</b> , 29, 368-79	5.7	33
218	Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice. <i>Hepatology</i> , <b>2017</b> , 65, 544-559	11.2	33
217	Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1257	6	33
216	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2 mice and human cholangiocarcinoma tumorigenesis. <i>Hepatology</i> , <b>2018</b> , 68, 1042-1056	11.2	32
215	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauroolithocholic acid-induced cholestasis in rat liver. <i>Hepatology</i> , <b>2010</b> , 52, 1758-68	11.2	32
214	Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 1427-34	6.1	32
213	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1066-1074	0.7	31
212	Clinical features and management of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 3313-27	5.6	31
211	Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, e8-e10	3.3	30

210	Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 870-6	13.6	30
209	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1127-1136	6.1	29
208	Changing nomenclature for PBC: From Cirrhosis to Cholangitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2015</b> , 39, e57-9	2.4	29
207	SNP analysis of genes implicated in T cell proliferation in primary biliary cirrhosis. <i>Clinical and Developmental Immunology</i> , <b>2005</b> , 12, 259-63		29
206	Dermatological Complications After Solid Organ Transplantation. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 54, 185-212	12.3	29
205	Tracing environmental markers of autoimmunity: introducing the infectome. <i>Immunologic Research</i> , <b>2013</b> , 56, 220-40	4.3	28
204	Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. <i>Tissue Antigens</i> , <b>2011</b> , 78, 65-8		28
203	Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. <i>Molecular and Cellular Proteomics</i> , <b>2012</b> , 11, 1885-97	7.6	28
202	Effect of anti-carbonic anhydrase antibodies on carbonic anhydrases I and II. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 1221-3	5.5	28
201	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , <b>2018</b> , 67, 1517-1524	19.2	28
200	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2076-2084.e2	6.9	27
199	The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. <i>Journal of Autoimmunity</i> , <b>2014</b> , 53, 55-66	15.5	27
198	The X chromosome in female-predominant autoimmune diseases. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1110, 57-64	6.5	27
197	The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. <i>Hepatology</i> , <b>2017</b> , 65, 1670-1682	11.2	26
196	Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. <i>Cancer Letters</i> , <b>2017</b> , 386, 179-188	9.9	26
195	Changing Nomenclature for PBC: From Cirrhosis to Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1536-8	0.7	26
194	Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. <i>European Journal of Immunology</i> , <b>2014</b> , 44, 945-54	6.1	26
193	Multi-Teaching Styles Approach and Active Reflection: Effectiveness in Improving Fitness Level, Motor Competence, Enjoyment, Amount of Physical Activity, and Effects on the Perception of Physical Education Lessons in Primary School Children. <i>Sustainability</i> , <b>2019</b> , 11, 405	3.6	25

192	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 633-43	4	25
191	Sex differences associated with primary biliary cirrhosis. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 610504		25
190	Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1997</b> , 11, 409-14	6.1	25
189	Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. <i>ACS Nano</i> , <b>2019</b> , 13, 4410-4423	16.7	24
188	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. <i>Cells</i> , <b>2020</b> , 9,	7.9	24
187	NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , <b>2018</b> , 2, 492-503	6	24
186	Geoeidemiology, Genetic and Environmental Risk Factors for PBC. <i>Digestive Diseases</i> , <b>2015</b> , 33 Suppl 2, 94-101	3.2	24
185	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , <b>2012</b> , 55, 1495-506	11.2	24
184	Quality of life and everyday activities in patients with primary biliary cirrhosis. <i>Hepatology</i> , <b>2007</b> , 46, 1836-43	6.43	24
183	Understanding short bowel syndrome: Current status and future perspectives. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 253-261	3.3	24
182	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 120-37	3.3	23
181	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 92	3	23
180	Bovine fetal microchimerism in normal and embryo transfer pregnancies and its implications for biotechnology applications in cattle. <i>Biotechnology Journal</i> , <b>2007</b> , 2, 486-91	5.6	23
179	Changing nomenclature for PBC: from Cirrhosis to Cholangitis. <i>Gut</i> , <b>2015</b> , 64, 1671-2	19.2	22
178	Immunopathogenesis of primary biliary cirrhosis: an old wives tale. <i>Immunity and Ageing</i> , <b>2011</b> , 8, 12	9.7	22
177	Genes and goals: an approach to microarray analysis in autoimmunity. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 414-22	13.6	22
176	The epigenetics of PBC: The link between genetic susceptibility and environment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 650-659	2.4	22
175	miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 570-580	5.8	21

174	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 432-5	3.3	21
173	The X chromosome and systemic sclerosis. <i>Current Opinion in Rheumatology</i> , <b>2006</b> , 18, 601-5	5.3	21
172	544 Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCS) in early primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , <b>2004</b> , 40, 159-160	13.4	21
171	A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. <i>Hepatology</i> , <b>2018</b> , 67, 232-246	11.2	21
170	Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2 mice and human primary sclerosing cholangitis. <i>Laboratory Investigation</i> , <b>2018</b> , 98, 1465-1477	5.9	20
169	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 436450	4.3	20
168	Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. <i>Tissue Antigens</i> , <b>2011</b> , 77, 239-43		20
167	A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 718-23	3.3	20
166	Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1109, 519-30	6.5	20
165	Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 1122-30	5.6	20
164	Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2017</b> , 53, 394-412	12.3	19
163	Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA. <i>Hepatology</i> , <b>2019</b> , 69, 2562-2578	11.2	19
162	Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2375-2377	6.9	19
161	Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. <i>Hormone and Metabolic Research</i> , <b>2009</b> , 41, 840-5	3.1	19
160	Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. <i>American Journal of Physiology - Cell Physiology</i> , <b>2011</b> , 300, C1078-89	5.4	19
159	The genetic basis of primary biliary cirrhosis: premises, not promises. <i>Gastroenterology</i> , <b>2008</b> , 135, 1044-73.3	13.3	19
158	Tamoxifen in treatment of primary biliary cirrhosis. <i>Hepatology</i> , <b>2004</b> , 39, 1175-6	11.2	19
157	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159612	3.7	19

156	Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 854-865	13.6	18
155	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. <i>FASEB Journal</i> , <b>2019</b> , 33, 10269-10279	0.9	18
154	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , <b>2021</b> , 73, 2099-2109	11.2	18
153	Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. <i>Hepatology</i> , <b>2020</b> , 71, 990-1008	11.2	18
152	Making Sense of Autoantibodies in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , <b>2016</b> , 20, 33-46	4.6	17
151	Apoptosis and innate immune system: novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 630-6	3.3	17
150	Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. <i>Liver International</i> , <b>2019</b> , 39 Suppl 1, 79-97	7.9	16
149	Serum autoantibodies: a road map for the clinical hepatologist. <i>Autoimmunity</i> , <b>2008</b> , 41, 27-34	3	16
148	Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 841-846	3.3	15
147	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 483-494	4.4	15
146	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , <b>2015</b> , 220, 1025-9	3.4	15
145	Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 698-702	3.3	15
144	Identification of Circulating MicroRNAs in Biliary Atresia by Next-Generation Sequencing. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2016</b> , 63, 518-523	2.8	15
143	Changing nomenclature for PBC: From Cirrhosis to Cholangitis? <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 924-6	3.3	14
142	Changing Nomenclature for PBC: From Cirrhosis to Cholangitis? <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1867-9	6.9	14
141	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 2090-2101	5.8	14
140	Methylation and liver cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, 564-71	2.4	14
139	It's as if PBC didn't exist: the illness experience of women affected by primary biliary cirrhosis. <i>Psychology and Health</i> , <b>2011</b> , 26, 1429-45	2.9	14

138	The enigma of primary biliary cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2005</b> , 28, 73-81	12.3	14
137	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules.. <i>Nature Immunology</i> , <b>2022</b> ,	19.1	14
136	Prognostic models in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , <b>2018</b> , 95, 171-178	15.5	14
135	The immunobiology of female predominance in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , <b>2018</b> , 95, 124-132	15.5	14
134	Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1093-1105	5.8	13
133	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2020</b> , 40, 1408-1414	7.9	13
132	Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2 mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2019</b> , 1865, 165557	6.9	13
131	Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2 mice. <i>Journal of Surgical Research</i> , <b>2017</b> , 217, 160-169	2.5	13
130	Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: association with disease severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2003</b> , 18, 1150-4	4	13
129	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , <b>2020</b> , 69, 1502-1509	19.2	13
128	Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1551-1565	5.8	12
127	Autonomic modulations of heart rate variability and performances in short-distance elite swimmers. <i>European Journal of Applied Physiology</i> , <b>2015</b> , 115, 825-35	3.4	12
126	New Therapeutic Targets in Autoimmune Cholangiopathies. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 117	4.9	12
125	Elevated circulating CD14CD16 monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization. <i>Clinical and Experimental Medicine</i> , <b>2016</b> , 16, 511-521	4.9	12
124	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. <i>Genes and Immunity</i> , <b>2015</b> , 16, 193-8	4.4	12
123	Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 523-33	3.3	12
122	Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. <i>Autoimmunity</i> , <b>2008</b> , 41, 92-9	3	12
121	Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2019</b> , 1865, 1525-1539	6.9	11

120	Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 54, 295-306	12.3	11
119	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 363-8	3.3	11
118	TNF-alpha polymorphisms in primary biliary cirrhosis: a northern and southern Italian experience. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1173, 557-63	6.5	11
117	From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 1121-1131	5.1	10
116	Knockout of Calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes. <i>Laboratory Investigation</i> , <b>2019</b> , 99, 764-776	5.9	10
115	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e1-e2	13.4	10
114	Fetal microchimerism in normal and embryo transfer bovine pregnancies. <i>Veterinary Research Communications</i> , <b>2007</b> , 31 Suppl 1, 205-7	2.9	10
113	Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. <i>Journal of Cellular Biochemistry</i> , <b>2008</b> , 104, 27-37	4.7	10
112	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100248	10.3	10
111	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 684-692.e6	6.9	10
110	DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. <i>Hepatology</i> , <b>2021</b> , 73, 144-159	11.2	10
109	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2017</b> , 65, 299-309	4	9
108	Toward precision medicine in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 843-50	3.3	9
107	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , <b>2021</b> , 160, 2483-2495.e26	13.3	9
106	Primary biliary cirrhosis: solving the enigma. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1051, 185-93	6.5	8
105	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1138-1146	6.1	8
104	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. <i>Annals of Hepatology</i> , <b>2020</b> , 19, 5-16	3.1	8
103	Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 140-147	5.3	8

102	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 572-581	13.4	8
101	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2019</b> , 1865, 2246-2256	6.9	7
100	Iron Metabolism in Liver Cancer Stem Cells. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 149	5.3	7
99	Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis. <i>Journal of Leukocyte Biology</i> , <b>2020</b> , 108, 659-671	6.5	7
98	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. <i>Autoimmunity Highlights</i> , <b>2012</b> , 3, 1-9	3.7	7
97	Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 965-966	13.4	7
96	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) $\geq$ 1 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 598438	4.9	7
95	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2020</b> , 40, 1121-1129	7.9	6
94	A National Hospital-Based Study of Hospitalized Patients With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1250-1257	6	6
93	Primary biliary cirrhosis. Foreword. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 253-4	7.3	6
92	Presence of fetal DNA in maternal plasma decades after pregnancy: further comments. <i>Human Genetics</i> , <b>2002</b> , 111, 576	6.3	6
91	Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28137	7	6
90	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 190-198	3.3	6
89	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , <b>2020</b> , 35, 141-148	2.5	6
88	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
87	"I Miss My Liver." Nonmedical Sources in the History of Hepatocentrism. <i>Hepatology Communications</i> , <b>2018</b> , 2, 982-989	6	6
86	Geoepidemiology and (epi-)genetics in primary biliary cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 34-35, 11-15	2.5	6
85	Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. <i>World Journal of Gastrointestinal Surgery</i> , <b>2021</b> , 13, 702-716	2.4	6

84	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	6
83	Precision medicine in primary biliary cholangitis. <i>Journal of Digestive Diseases</i> , <b>2019</b> , 20, 338-345	3.3	5
82	INTERPRETATION AND PERCEPTION OF TWO DIFFERENT KUMITE FIGHTING INTENSITIES THROUGH AN INTEGRATED APPROACH TRAINING IN INTERNATIONAL LEVEL KARATEKAS: AN EXPLORATORY STUDY. <i>Perceptual and Motor Skills</i> , <b>2015</b> , 121, 333-49	2.2	5
81	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	5
80	Study of the influence of heme oxygenase 1 gene single nucleotide polymorphism (rs2071746) on esophageal varices among patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 888-892	2.2	5
79	Intrahepatic cholestasis of pregnancy: a further important step in dissecting its genetic architecture. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 266-7	3.3	5
78	Interpretation and perception of slow, moderate, and fast swimming paces in distance and sprint swimmers. <i>Perceptual and Motor Skills</i> , <b>2014</b> , 118, 833-49	2.2	5
77	Decreased serum leptin levels in primary biliary cirrhosis: a link between metabolism and autoimmunity?. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1051, 211-7	6.5	5
76	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1688-1697	6.9	5
75	Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. <i>Liver International</i> , <b>2020</b> , 40, 2590-2601	7.9	5
74	Better end points needed in primary sclerosing cholangitis trials. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 143-144	24.2	5
73	Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis even in patients without biochemical improvements. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S8	13.4	5
72	The genetic architecture of primary biliary cholangitis. <i>European Journal of Medical Genetics</i> , <b>2021</b> , 64, 104292	2.6	5
71	Treatment of PBC-A step forward. <i>Liver International</i> , <b>2017</b> , 37, 503-505	7.9	4
70	Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. <i>Diseases (Basel, Switzerland)</i> , <b>2020</b> , 8,	4.4	4
69	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. <i>Journal of Autoimmunity</i> , <b>2020</b> , 113, 102503	15.5	4
68	Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. <i>Cellular and Molecular Immunology</i> , <b>2018</b> , 15, 610-617	15.4	4
67	X chromosome in autoimmune diseases. <i>Expert Review of Clinical Immunology</i> , <b>2008</b> , 4, 591-7	5.1	4

66	Role of X chromosome defects in primary biliary cirrhosis. <i>Hepatology Research</i> , <b>2007</b> , 37 Suppl 3, S384-85.1		4
65	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , <b>2021</b> , 74, 1496-1508	11.2	4
64	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 5890-5907	5.6	4
63	Human $\beta$ -Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , <b>2017</b> , 8, e80	4.2	3
62	Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency. <i>Journal of Digestive Diseases</i> , <b>2019</b> , 20, 363-370	3.3	3
61	Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. <i>Cells</i> , <b>2020</b> , 9,	7.9	3
60	Effects of Acute Carnosine and $\beta$ -Alanine on Isometric Force and Jumping Performance. <i>International Journal of Sports Physiology and Performance</i> , <b>2016</b> , 11, 344-9	3.5	3
59	Soluble CD40L in plasma of patients with primary biliary cirrhosis. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1051, 205-10	6.5	3
58	Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , <b>2019</b> , 10, 3931-3938	3.3	3
57	Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. <i>Liver International</i> , <b>2021</b> ,	7.9	3
56	Immune-mediated bile duct injury: The case of primary biliary cirrhosis. <i>World Journal of Gastrointestinal Pathophysiology</i> , <b>2010</b> , 1, 118-28	3.2	3
55	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 2227-2234	5.2	3
54	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 367-374	3.3	3
53	Individualizing Care: Management Beyond Medical Therapy. <i>Clinics in Liver Disease</i> , <b>2018</b> , 22, 545-561	4.6	3
52	Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. <i>Liver International</i> , <b>2019</b> , 39, 2124-2135	7.9	2
51	Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 21-22	3.3	2
50	FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e390-e391	13.4	2
49	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , <b>2012</b> , 3, 127-32	3.7	2

48	The search for a practical approach to emerging diseases: the case of severe acute respiratory syndrome (SARS). <i>Autoimmunity</i> , <b>2002</b> , 9, 113-7		2
47	T-cell receptor polymorphism in primary biliary cirrhosis. <i>Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societ� Italiana Di Medicina Interna</i> , <b>2003</b> , 18, 149-53		2
46	Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis". <i>Disease Markers</i> , <b>2020</b> , 2020, 2453908	3.2	1
45	Novel treatments targeting immune-related mechanisms in primary biliary cholangitis. <i>Clinical Liver Disease</i> , <b>2016</b> , 8, 127-131	2.2	1
44	Primary sclerosing cholangitis is changing clinical spectrum and old biomarkers disclose an innovative role: the case of alkaline phosphatase. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 268-9	3.3	1
43	WHAT IS AN AUTOANTIBODY? <b>2007</b> , 3-6		1
42	Cytokines in Liver Health and Disease <b>2007</b> , 83-93		1
41	NUCLEAR ENVELOPE PROTEIN AUTOANTIBODIES/ANTILAMIN AUTOANTIBODIES <b>2007</b> , 191-196		1
40	ANTINUCLEAR ANTIBODIES: GENERAL INTRODUCTION <b>2007</b> , 129-133		1
39	ANTIMITOCHONDRIAL ANTIBODIES <b>2007</b> , 473-477		1
38	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. <i>Immunotherapy</i> , <b>2021</b> ,	3.8	1
37	MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
36	Open challenges in the management of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2020</b> ,	1.6	1
35	E. coli and the Etiology of Human PBC: Anti-mitochondrial Antibodies and Spreading Determinants. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
34	Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. <i>Endocrine</i> , <b>2021</b> , 75, 942	4	1
33	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 33,	2.2	1
32	Primary Biliary Cirrhosis and Autoimmune Cholangitis <b>2007</b> , 235-247		1
31	Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis. <i>Acta Hepatologica Japonica</i> , <b>2009</b> , 50, 51-59	0.3	1

30	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. <i>Hepatology</i> , <b>2020</b> , 72, 359-360	11.2	1
29	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e138-e139	4.5	1
28	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 673487	8.4	1
27	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules		1
26	The seat of life. What a lesson from the stigmatized saints. <i>Liver International</i> , <b>2021</b> , 41, 1675-1676	7.9	1
25	The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. <i>Liver International</i> , <b>2021</b> ,	7.9	1
24	Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 5520-5535	5.6	1
23	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. <i>Journal of Translational Autoimmunity</i> , <b>2021</b> , 4, 100081	4.1	1
22	Cytokines in the Liver: Cytokine Mechanisms in Liver Health and Disease <b>2017</b> , 75-96		0
21	Genetics of Autoimmune Liver Diseases <b>2020</b> , 69-85		0
20	The mode of dexamethasone decoration influences Avidin-nucleic-acid-Nano-assembly organ biodistribution and in vivo drug persistence. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2021</b> , 102497	6	0
19	Acute carnosine and Alanine supplementation increase the compensated part of the ventilation versus work rate relationship during a ramp incremental cycle test in physically active men. <i>Journal of Sports Medicine and Physical Fitness</i> , <b>2021</b> , 61, 37-43	1.4	0
18	Cost of illness of Primary Biliary Cholangitis - a population-based study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1167-1170	3.3	0
17	Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 1123-1138	5.6	0
16	The Epigenetics of Primary Biliary Cholangitis <b>2018</b> , 251-272		
15	Smooth Muscle Autoantibodies <b>2014</b> , 491-495		
14	Infection and Autoimmune Liver Diseases <b>2015</b> , 839-857		
13	OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study. <i>Gut</i> , <b>2014</b> , 63, A15-A16	19.2	

- 12 Nuclear Envelope Protein Autoantibodies/Antilamin Autoantibodies **2014**, 219-223
- 11 Hunting for fibrosis progression genes in hepatitis C patients. *Clinical Science*, **2011**, 120, 285-6 6.5
- 10 Autoantibody Recognition of Functional Sites **2006**, 473-491
- 9 Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis. *Gut*, **2005**, 54, 1665 19.2
- 8 Combined ursodeoxycholic acid/secretin treatment reduces biliary senescence and liver fibrosis in a murine model of late stage primary biliary cholangitis. *FASEB Journal*, **2020**, 34, 1-1 0.9
- 7 Individualizing Care: Management Beyond Medical Therapy. *Surgical Oncology Clinics of North America*, **2020**, 29, 87-103 2.7
- 6 Old and novel prognostic biomarkers in primary biliary cholangitis. *Expert Opinion on Orphan Drugs*, **2021**, 9, 123-131 1.1
- 5 Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. *Digestive and Liver Disease*, **2021**, 53, 1603-1609 3.3
- 4 Reply to: "A spotlight on natural killer cells in primary biliary cholangitis". *Journal of Hepatology*, **2021**, 74, 255-256 13.4
- 3 Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?. *Journal of Translational Autoimmunity*, **2021**, 4, 100124 4.1
- 2 Elastography in Autoimmune Liver Diseases **2021**, 91-103
- 1 Hepatitis C virus infection and diabetes: a complex bidirectional relationship.. *Diabetes Research and Clinical Practice*, **2022**, 109870 7.4